Sep. 17 at 7:32 AM
$PFE raised the top line. COVID still collapsed.
Comirnaty -34% operational. Paxlovid -95%. Non-COVID +5%. New and acquired products +18%. Guidance now
$60.5B-
$62.5B after a
$500M midpoint raise. COVID outlook cut
$1B to about
$4B.
Innovent deal:
$650M upfront, up to
$9.85B milestones,
$0.10 EPS hit in Q3.
Seagen mix is uneven. Padcev +23%. Other inherited oncology brands fell. SigVie-002 miss triggered
$3.8B IPR&D impairment. Total write-downs
$4.3B. Reported EPS $(0.04).
Savings target is
$9.7B through 2029. Patent replacement is the real test.
$PFE $MRK $LLY $ABBV $BMY
#Pfizer #Pharma #Oncology #PatentCliff #Earnings
